Algorithmic Biologics published a blog post titled Screening vs Monitoring in Cancer: Why One Assay Design Does Not Fit.
Public source
Publisher name
Public post
Read our latest blog on 'Screening vs Monitoring in Cancer: Why One Assay Design Does Not Fit' https://lnkd.in/gFt8eRu2 AlgoBio builds ultra-multiplexed universal detect…
Company
Algorithmic Biologics
Bringing scale efficiencies to molecular discovery and diagnostics.
- Industry
- Biotechnology Research
- Location
- Foster City, US
- Company size
- 11–50 employees
About Algorithmic Biologics
We are a deep-tech company combining mathematics, computer science, and biology to transform molecular assay design at scale. Our Sequence Transduction technology enables highly multiplexed, cost-effective diagnostics, detecting hundreds of targets in minimal reactions with MRD- level sensitivity (<0.02%) and rapid assay development (1–3 months, ~98% success). Our proprietary Tapestry platform enables software-driven combinatorial multiplexing atop standard molecular tests like NGS and PCR, delivering significant cost savings (of up to 60%) with improved accuracy. Tapestry partners with diagnostic and research labs globally to execute large volume molecular testing. We are a true partner to biopharma, diagnostic manufacturers and molecular testing labs worldwide. We have offices in San Francisco and Bangalore.
See moreLatest activity
Latest activity from Algorithmic Biologics
2 signals
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
1Cell.Ai Inc.
1Cell.Ai Inc. published a study in Cancer Research, an AACR Journals, highlighting the potential of comprehensive ctDNA profiling in treatment-naïve patients with early-stage breast cancer.
Research & Knowledge
Eclipsebio
Eclipsebio published a review by Ojalvo et al. describing the process of individualized neoantigen therapy across three phases involving formalin-fixed paraffin-embedded tumor blocks, whole blood for germline control and HLA typing, and a CAP/CLIA- and ISO13485-certified lab for histopathology, nucleic acid extraction, and next-generation sequencing.
Research & Knowledge
Altum Sequencing
Altum Sequencing developed AltumTRACKseq, a tumor-informed strategy designed to monitor patient-specific molecular signals through high-sensitivity NGS.
Research & Knowledge
Oxford Nanopore Technologies
Oxford Nanopore Technologies published a case study on researchers using Oxford Nanopore sequencing to uncover hidden cancer signals for earlier detection and monitoring.
Research & Knowledge
Panome Bio